ライフサイエンスコーパス: didanosine

1 e double-combination regimen (zidovudine and didanosine).

2 he risk of NCPH in HIV patients treated with didanosine.

3 e zidovudine, didanosine, or zidovudine plus didanosine.

4 ovudine plus zalcitabine, or zidovudine plus didanosine.

5 ne plus 2.25 mg of zalcitabine; or 400 mg of didanosine.

6 amivudine and abacavir, but not stavudine or didanosine.

7 ide drugs such as zidovudine, stavudine, and didanosine.

8 or combination therapy with zidovudine plus didanosine.

9 All patients received zidovudine and didanosine; 100 received nevirapine and 98 received plac

10 alone (32 percent) than with zidovudine plus didanosine (18 percent; relative hazard ratio, 0.50; P<0

11 and 2) open-label zidovudine (600 mg/d) and didanosine (400 mg/d for patients weighing > or = 60 kg)

12 stavudine/lamivudine (17.6%), and stavudine/didanosine (5.4%).

13 ovudine; 600 mg of zidovudine plus 400 mg of didanosine; 600 mg of zidovudine plus 2.25 mg of zalcita

14 the 363 patients assigned to zidovudine plus didanosine, 63 percent of the 367 assigned to zidovudine

15 t; relative hazard ratio, 0.54; P<0.001), or didanosine alone (22 percent; relative hazard ratio, 0.6

16 r neutropenia was seen in patients receiving didanosine alone (P=0.036).

17 At the end of the study, didanosine alone had an efficacy similar to that of zido

18 ith zidovudine alone as compared with either didanosine alone or combination therapy with zidovudine

19 HIV-infected children, treatment with either didanosine alone or zidovudine plus didanosine was more

20 didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression of HIV disease an

21 The efficacy of didanosine alone was similar to that of the combination

22 eated with zidovudine alone, 0.65+/-0.07 for didanosine alone, 0.93+/-0.10 for zidovudine plus didano

23 ndomly assigned to receive zidovudine alone, didanosine alone, zidovudine plus didanosine, or zidovud

24 ine plus zalcitabine, and 0.69 (P=0.019) for didanosine alone.

25 An association between use of zidovudine and didanosine and a rare but life-threatening syndrome of h

26 lacebo once daily) (n = 285) plus open-label didanosine and efavirenz, once daily.

27 ce-daily stavudine when used with once-daily didanosine and efavirenz.

28 Didanosine and hydroxyurea were added to the antiretrovi

29 Thus, combination therapy with didanosine and IFN-alpha can be safely administered to p

30 as undertaken to evaluate the combination of didanosine and interferon-alpha (INF-alpha) in human imm

31 cond regimen, as compared with starting with didanosine and stavudine (hazard ratio, 0.68), and signi

32 vudine and lamivudine or a regimen including didanosine and stavudine in combination with either nelf

33 nz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine wi

34 lamivudine (but not efavirenz combined with didanosine and stavudine) appeared to delay the failure

35 d to make them more convenient (specifically didanosine and stavudine).

36 osine alone, 0.93+/-0.10 for zidovudine plus didanosine, and 0.89+/-0.06 for zidovudine plus zalcitab

37 uple-drug therapy with adefovir, lamivudine, didanosine, and efavirenz provides pronounced and durabl

38 eatment with adefovir dipivoxil, lamivudine, didanosine, and efavirenz.

39 version with the combination of hydroxyurea, didanosine, and indinavir.

40 1 associated with resistance to zidovudine, didanosine, and lamivudine by genotyping by an oligonucl

41 s selected during treatment with zidovudine, didanosine, and nevirapine differed among individuals an

42 fection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sus

43 Zidovudine, didanosine, and nevirapine were administered in combinat

44 ricitabine, abacavir, zidovudine, stavudine, didanosine, and tenofovir and a specific GSS (sGSS) defi

45 Drugs such as stavudine and didanosine are associated with serious metabolic complic

46 eath were 0.64 (P=0.005) for zidovudine plus didanosine, as compared with zidovudine alone, 0.77 (P=0

47 CD4 cell counts increased with didanosine but declined following the addition of IFN-al

48 cell responses were seen in this zidovudine-didanosine combination pilot study relative to codon 215

49 erval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% co

50 study, patients assigned to zidovudine plus didanosine combination therapy experienced a significant

51 2 weeks, followed by 12 weeks of hydroxyurea/didanosine combination therapy for all patients.

52 ficacy for 38 patients receiving hydroxyurea/didanosine combination therapy with findings in 42 perso

53 The hydroxyurea/didanosine combination was well tolerated.

54 agnitude in the sequence zalcitabine (ddC) > didanosine (ddI metabolized to ddA) > stavudine (d4T) >>

55 zidovudine (AZT) plus zalcitabine (ddC) and didanosine (ddI) develop AZT resistance mediated by muta

56 n from a larger efficacy trial of 2 doses of didanosine (ddI) monotherapy (Pediatric AIDS Clinical Tr

57 als Group 152 study, which demonstrated that didanosine (ddI) or zidovudine + ddI treatments were sup

58 Didanosine (ddI) pharmacokinetics in antepartum and post

59 nscriptase (RT) develops as a consequence of didanosine (ddI) therapy and is associated with a decrea

60 randomized either to add stavudine (d4T) or didanosine (ddI) to their current regimen or to switch t

61 In a trial (ACTG 241) of zidovudine/didanosine (ddI) versus zidovudine/ddI/nevirapine in nuc

62 1 (HIV-1) strains that confer resistance to didanosine (ddI) was analyzed in 2 groups of patients re

63 IC(50) values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determin

64 The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleoti

65 avir, zidovudine (AZT), abacavir, stavudine, didanosine (ddI), and lamivudine] individually or in com

66 Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable.

67 airs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/3TC, d4T/ddI, and ddI/

68 unodeficiency virus type 1 who switched to a didanosine (ddI)-containing triple- or quadruple-drug re

69 ombination therapy with zidovudine (AZT) and didanosine (ddI).

70 [stavudine (D4T)] and 2'-3'-dideoxyinosine [didanosine (ddI)] likewise stimulated template-switch mu

71 udine [AZT (3'-azido-3'-deoxythymidine)] and didanosine [ddI (2',3'-dideoxyinosine)], in cultured hum

72 ral drugs zidovudine, indinavir sulfate, and didanosine, demonstrating that this model can also be us

73 ne-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavi

74 n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-

75 ogenomics in NCPH in HIV patients with prior didanosine exposure.

76 Didanosine failed to reduce the suppressive effects of H

77 r 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1 for 30 days.

78 experienced subjects received zidovudine and didanosine for 30 weeks followed by 30 weeks of didanosi

79 with zidovudine alone or in combination with didanosine from 22 patients (8 zidovudine-naive and 14 z

80 .20); a higher percentage of the hydroxyurea/didanosine group below the assay's detection limit (500

81 cells for the hydroxyurea/didanosine versus didanosine group of 0 versus 43 cells/mm3 (P=.045), alth

82 s load between hydroxyurea/didanosine versus didanosine groups of -0.93 versus -0.74 log10 copies/mL

83 ination regimen (nevirapine, zidovudine, and didanosine) had an 18% higher mean absolute CD4 cell cou

84 Adding nevirapine to zidovudine and didanosine improved the long-term immunologic and virolo

85 treatment consisted of the nucleoside analog didanosine in the first 43 patients enrolled before Dece

86 Abacavir and didanosine increased rolling, adhesion and emigration in

87 viral infection with the nucleoside analogue didanosine is known to cause portal hypertension in a su

88 pies/mL received a once-daily SIT regimen of didanosine, lamivudine, and efavirenz.

89 lity testing of five isolates to zidovudine, didanosine, lamivudine, and nevirapine demonstrated susc

90 tibility of 16 HIV-1 isolates to zidovudine, didanosine, lamivudine, and nevirapine in MT-2 cells.

91 efficacy similar to that of zidovudine plus didanosine (median follow-up, 32 months) (relative risk

92 on therapy with findings in 42 persons given didanosine monotherapy for 12 weeks, followed by 12 week

93 benefits were maintained in this group with didanosine monotherapy.

94 anosine for 30 weeks followed by 30 weeks of didanosine monotherapy.

95 Other agents included zidovudine, didanosine, nevirapine, and saquinavir.

96 nges in susceptibility to ABC, 3TC, TDF, and didanosine on titration of K65R and/or M184V with wild-t

97 teers with >200 x 10(6) CD4 cells/L received didanosine (one 100-, 250-, or 375-mg sachet twice daily

98 Didanosine (one 375-mg sachet twice daily) was substitut

99 been identified, such as co-prescription of didanosine or boosted protease inhibitor, preexisting CK

100 me of the antiretroviral drugs (zalcitabine, didanosine or stavudine).

101 therapy consisted of zidovudine plus either didanosine or stavudine.

102 mbination therapy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine

103 ther changing to combination therapy (adding didanosine or zalcitabine) or sequential monotherapy (ch

104 bine) or sequential monotherapy (changing to didanosine or zalcitabine) significantly improves surviv

105 ine alone or zidovudine combined with either didanosine or zalcitabine.

106 and randomly assigned to receive zidovudine, didanosine, or zidovudine plus didanosine.

107 ine alone, didanosine alone, zidovudine plus didanosine, or zidovudine plus zalcitabine.

108 regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir for 7 days, (B)

109 20 patients evaluable for codon 74 (site of didanosine resistance) had virus that remained wild type

110 Didanosine-resistance mutations arose rarely.

111 Therapy with zidovudine plus didanosine resulted in more gastrointestinal adverse eff

112 We previously showed that a didanosine-selected mutation in pNL4-3 background confer

113 rd ratio for a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63

114 (hazard ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01

115 eived the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for

116 lure than the three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for

117 at received the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the

118 -nevirapine, stavudine-zidovudine, stavudine-didanosine, stavudine-saquinavir, stavudine-nevirapine,

119 randomized ART-naive individuals to receive didanosine-stavudine or zidovudine-lamivudine, combined

120 RMs to drugs not received, such as abacavir, didanosine, tenofovir, etravirine, and rilpivirine.

121 However, in the presence of zidovudine or didanosine, the comparative order for replication was HI

122 In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-17

123 HIV-1-infected patients in combination with didanosine; therefore, we investigated the impact of HU

124 administration of a dideoxynucleoside drug, didanosine, to transgenic mice expressing the HIV coat p

125 why NCPH only develops in a small subset of didanosine-treated patients.

126 y found that thrombocytopenia, splenomegaly, didanosine use, elevated aminotransferases, and an eleva

127 dian change in CD4 cells for the hydroxyurea/didanosine versus didanosine group of 0 versus 43 cells/

128 n decrease in virus load between hydroxyurea/didanosine versus didanosine groups of -0.93 versus -0.7

129 sponsible for activation of AIDS drug ddIno (didanosine, Videx) can also, albeit less efficiently, ac

130 Zidovudine or didanosine was added to cultures in an attempt to revers

131 dine therapy, treatment with zidovudine plus didanosine was associated with a relative risk of diseas

132 h either didanosine alone or zidovudine plus didanosine was more effective than treatment with zidovu

133 levels; and plasma levels of zidovudine and didanosine were measured in patients enrolled at half th

134 se-transcriptase inhibitors, zidovudine, and didanosine were not permitted.

135 V-related factors, apart from treatment with didanosine, were associated with CD4 decline.

136 Exposure to didanosine, which is also a purine analogue, predisposes

137 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease.

138 ults support the association of abacavir and didanosine with CV diseases.

139 sive therapy with combination zidovudine and didanosine with or without nevirapine were identified in

140 zidovudine and zalcitabine or zidovudine and didanosine would delay the emergence of zidovudine-resis

141 nt, whereas susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and lamivudine) decre

142 lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine.

143 ilities of PERV RT to lamivudine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20

144 Treatment with zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine a